Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease

Objective To investigate the effect of sequential Helicobacter pylori eradication therapy on serum osteoprotegerin levels in patients with H. pylori infection and co-existing inflammatory bowel disease (IBD). Methods Three groups of patients were involved in this observational cross-sectional study:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hussam Murad, Misbahuddin Rafeeq, Mahmoud Mosli, Mamdouh Gari, Mohammed Basheikh
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c194fbc0a7a345159d0029a4b2970c30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c194fbc0a7a345159d0029a4b2970c30
record_format	dspace
spelling	oai:doaj.org-article:c194fbc0a7a345159d0029a4b2970c302021-12-02T08:04:38ZEffect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease1473-230010.1177/03000605211060648https://doaj.org/article/c194fbc0a7a345159d0029a4b2970c302021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211060648https://doaj.org/toc/1473-2300Objective To investigate the effect of sequential Helicobacter pylori eradication therapy on serum osteoprotegerin levels in patients with H. pylori infection and co-existing inflammatory bowel disease (IBD). Methods Three groups of patients were involved in this observational cross-sectional study: IBD (n = 83), H. pylori infection (HP, n = 68), and H. pylori infection with co-existing IBD (HP + IBD, n = 52). These groups were compared with a normal control group (NC, n = 50). Serum osteoprotegerin, serum bone alkaline phosphatase (BALP), and fecal calprotectin (FC) levels were measured. Results Serum osteoprotegerin levels were significantly correlated with the simple endoscopic score for Crohn’s disease and Mayo score for ulcerative colitis. The receiver operating characteristic analysis of osteoprotegerin revealed high values for the area under the curve, sensitivity, and specificity. Discriminant analysis illustrated that osteoprotegerin levels significantly differentiated patients with IBD from healthy controls. Osteoprotegerin and FC levels distinguished the IBD and HP + IBD groups from the NC and HP groups. Conclusions Sequential eradication therapy did not affect serum osteoprotegerin levels in patients with H. pylori infection and co-existing IBD. Serum osteoprotegerin elevation might be a marker for IBD development in patients with past or current H. pylori infection.Hussam MuradMisbahuddin RafeeqMahmoud MosliMamdouh GariMohammed BasheikhSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hussam Murad Misbahuddin Rafeeq Mahmoud Mosli Mamdouh Gari Mohammed Basheikh Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
description	Objective To investigate the effect of sequential Helicobacter pylori eradication therapy on serum osteoprotegerin levels in patients with H. pylori infection and co-existing inflammatory bowel disease (IBD). Methods Three groups of patients were involved in this observational cross-sectional study: IBD (n = 83), H. pylori infection (HP, n = 68), and H. pylori infection with co-existing IBD (HP + IBD, n = 52). These groups were compared with a normal control group (NC, n = 50). Serum osteoprotegerin, serum bone alkaline phosphatase (BALP), and fecal calprotectin (FC) levels were measured. Results Serum osteoprotegerin levels were significantly correlated with the simple endoscopic score for Crohn’s disease and Mayo score for ulcerative colitis. The receiver operating characteristic analysis of osteoprotegerin revealed high values for the area under the curve, sensitivity, and specificity. Discriminant analysis illustrated that osteoprotegerin levels significantly differentiated patients with IBD from healthy controls. Osteoprotegerin and FC levels distinguished the IBD and HP + IBD groups from the NC and HP groups. Conclusions Sequential eradication therapy did not affect serum osteoprotegerin levels in patients with H. pylori infection and co-existing IBD. Serum osteoprotegerin elevation might be a marker for IBD development in patients with past or current H. pylori infection.
format	article
author	Hussam Murad Misbahuddin Rafeeq Mahmoud Mosli Mamdouh Gari Mohammed Basheikh
author_facet	Hussam Murad Misbahuddin Rafeeq Mahmoud Mosli Mamdouh Gari Mohammed Basheikh
author_sort	Hussam Murad
title	Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
title_short	Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
title_full	Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
title_fullStr	Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
title_full_unstemmed	Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
title_sort	effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/c194fbc0a7a345159d0029a4b2970c30
work_keys_str_mv	AT hussammurad effectofsequentialeradicationtherapyonserumosteoprotegerinlevelsinpatientswithinfectionandcoexistinginflammatoryboweldisease AT misbahuddinrafeeq effectofsequentialeradicationtherapyonserumosteoprotegerinlevelsinpatientswithinfectionandcoexistinginflammatoryboweldisease AT mahmoudmosli effectofsequentialeradicationtherapyonserumosteoprotegerinlevelsinpatientswithinfectionandcoexistinginflammatoryboweldisease AT mamdouhgari effectofsequentialeradicationtherapyonserumosteoprotegerinlevelsinpatientswithinfectionandcoexistinginflammatoryboweldisease AT mohammedbasheikh effectofsequentialeradicationtherapyonserumosteoprotegerinlevelsinpatientswithinfectionandcoexistinginflammatoryboweldisease
_version_	1718398686302568448

Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease

Ejemplares similares